Yike Wang

Oct 8, 2024 | onlinelibrary.wiley.com | Shuai Zhang |Engineering Chengdu |Yike Wang |Huachun Wang

CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Supporting Information Filename Description app56379-sup-0001-supinfo.docxWord 2007 document , 382.7 KB Data S1. Supporting Information. REFERENCES 1, , J. Polym. Sci., Part A: Polym. Chem. 1999, 37, 2105. 2, , Polymer 2007, 48, 91. 3, , , J. Appl. Polym. Sci. 2014, 131, 39746. 4, , , , , , J. Polym. Sci., Part A: Polym. Chem. 2014, 52, 1662. 5, , , , , , Polymer 2016, 84, 365. 6, , , , Polym.

May 6, 2024 | ascpt.onlinelibrary.wiley.com | Peng Yun Chen |Yanyan Zhang |Yike Wang |Ke Ma

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Adebrelimab, a novel anti-PD-L1 antibody, has been approved by the National Medical Products Administration (NMPA) of China as an intravenous infusion for use in combination with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Adebrelimab is administered currently at a body weight-based dose of 20 mg/kg q3w. WHAT QUESTION DID THIS STUDY ADDRESS?